Immune Cell Changes in Prostate Cancer Patients Receiving Brachytherapy
Studies immune cells in blood and tissue during prostate cancer radiation treatment.
Plain-language title generated from the registry record
Registry title: Immune Biomarkers in Prostate Cancer Patients Treated With Brachytherapy
Key facts
- Where
- Augsburg, Erlangen, and Munich, GermanySee the 3 sites
Where in Germany
- Klinik für StrahlentherapieAugsburg, GermanyNot yet recruiting
- Strahlenklinik ErlangenErlangen, GermanyTaking people
- Klinik und Poliklinik für Strahlentherapie und RadioonkologieMunich, GermanyNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Erlangen-Nürnberg Medical School
- Trial code
- NCT07131956
- Record updated
- 18 November 2025
- Original description
Analysis of peripheral immune cells before, during, and after brachytherapy treatment. Corresponding analysis of tissue samples collected during brachytherapy treatment.Read full original descriptionShow less
Immune Biomarkers in Prostate Cancer Patients Treated With Brachytherapy (ImmunBioProBrachy)
Analysis of peripheral immune cells before, during, and after brachytherapy treatment. Corresponding analysis of tissue samples collected during brachytherapy treatment.
Inclusion: Primary treatment with I-125 seeds or HDR-BT; No previous treatment for prostate cancer; Age ≥ 18 years; HDR- or PDR-BT; No radiation therapy within three months before salvage treatment; Complete documentation available on previous treatment for prostate cancer; No history of prostatectomy; Age ≥ 18 years.
Exclusion: patients under bloodthinning medication; Pre-existent auto-immune disease; substance abuse.